Promising ROd-cone DYstrophy Gene therapY (PRODYGY)

A Phase I/II Study to Assess the Safety and Tolerability of a Single Subretinal Administration of SPVN06 Gene Therapy in Subjects With Rod-Cone Dystrophy (RCD)

This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene (Step 1), or in any RCD-causative gene (Step 2).

Study Overview

• Status: Active, not recruiting
• Conditions: Retinitis Pigmentosa
• Intervention / Treatment: Drug: SPVN06

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• France
  • Paris, France, 75012
    • CHNO XV-XX Paris - CIC 1423
• United States
  • Florida
    • Miami, Florida, United States, 33136
      • Bascom Palmer Eye Institute/University of Miami
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Mass Eye and Ear
  • Oregon
    • Portland, Oregon, United States, 97239
      • Casey Eye Institute
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • UPMC Eye Center
  • Texas
    • Dallas, Texas, United States, 75231
      • Retina Foundation of the Southwest

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Subjects will be eligible to participate in this study only if all the following criteria apply:

1. Able to give signed informed consent and comply with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
2. Age ≥18 years at the time of ICF signature.
3. Subjects of either gender previously diagnosed with advanced RCD due to: in Step 1, biallelic mutations in the rod cGMP phosphodiesterase 6 beta (PDE6B) or rod cGMP phosphodiesterase alpha (PDE6A) genes, or a monoallelic dominant mutation in the rhodopsin (RHO) gene; in Step 2, mutations in any RCD-causative gene (such as variants classified as 'pathogenic/likely pathogenic'). The genotyping results must be documented before the initiation of the Screening Visit. Subjects should be retested by the investigator if their genotyping tests were not performed within the 7 previous years, or if they were not performed by an accredited laboratory.

4. Advanced stage is defined as a stage of the natural history of the disease where both distance visual acuity and visual field are affected in both eyes. The Study Eye should meet the definition of one of the following substages within the advanced stage (monocular measurements, horizontal axis of isopter III4e for the visual field):

   • Severe stage is defined by both a BCVA below or equal to 20/200 and above or equal to 20/800, and a visual field below or equal to 20 degrees (subjects of Cohorts 1 to 3)
   • Intermediate stage is defined by both a BCVA below or equal to 20/40 and above or equal 20/200, and a visual field below or equal to 30 degrees (subjects of Cohorts 4 to 6)
5. For subjects with severe advanced RCD enrolled in Step 1 only, the difference in visual acuity between the two eyes of a given subject should be equal to or below 0.3 logarithm of the minimal angle (LogMAR) (≤3 ETDRS lines), with a tolerance margin of 3 ETDRS letters.
6. Clinical diagnosis of RCD based on past medical and family history, mid-peripheral visual field dysfunction, photopsia, night blindness (nyctalopia), and fundoscopic appearance (including but not restricted to bone spicule pigmentation, attenuation of the retinal vessels, and waxy pallor of the optic nerve).
7. Diagnosis of RCD is confirmed on prior full-field ERG (any previously performed ERG is acceptable).
8. Documented preservation of cone inner and outer segments considered good enough by the investigator for the subject to be included in the study.
9. Negative serum pregnancy test for women of childbearing potential (please refer to Schedule of Assessments for details).

10. Women of childbearing potential (WOCBP) and men and/or their partner(s) of childbearing potential must agree to use a highly effective contraceptive method. This applies to the time period between ICF signature and 12 months after SPVN06 subretinal injection SRI (i.e., no longer applicable to subjects of Cohort 4 after randomization). The definition of highly effective contraceptive methods follows CTFG recommendations. Highly effective contraceptive methods are limited to:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Intravaginal
      • Transdermal

    • Progestogen-only hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Injectable
      • Implantable
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner
    • Sexual abstinence
11. Subjects must be affiliated to a health security system, if they are included in a clinical site based in France (per law).
12. No out-of-range values for clinical laboratory tests, however, if outside, must be considered as non-clinically relevant by the investigator using a multidisciplinary approach and compatible with a participation in the clinical study.
13. 12-lead electrocardiogram within normal limits, however, when outside, must be documented by the investigator using a multidisciplinary approach as not clinically relevant and compatible with a participation in the clinical study. Nota bene: This criterion of eligibility is only applicable to subjects assigned to a treatment cohort (Cohorts 1, 2, 3, 5, or 6), and is not required to authorize randomization in Step 2.
14. Physical examination without any clinical findings of clinical relevance (per medical/anesthesia staffs judgment) that could compromise participation in the clinical study or could affect the collection and/or evaluation of the study parameters. The findings of clinical relevance considered as contraindications to SPVN06 treatment include, but are not limited to, pulmonary pathology such as COPD, asthma, cardiac conditions such as congestive heart failure or valve disease, renal issues such as renal insufficiency and endocrine issues such as diabetes.

Exclusion Criteria:

Subjects are not eligible to participate in this study if any of the following criteria apply:

1. Subjects with prior administration of any gene therapy or any previous treatment with stem cell therapy for ocular or non-ocular disease.
2. Subjects participating in another clinical trial and receiving an investigational medicinal product (IMP) within 5 half-lives or 90 days prior to the injection of SPVN06.
3. Subjects with systemic disease or other pathology not related to their diagnosis of RCD, and whose symptoms or associated treatments may affect vision, for example cancers or pathology of the central nervous system.
4. Subjects with narrow irido-corneal angles or any other medical situation contraindicating pupillary dilation.
5. Subjects known to be allergic to any of the delivery vehicle constituents or to any other drugs planned to be used during the clinical study.
6. Subjects with known allergies to corticosteroids, or who will be unable to tolerate the corticosteroid regimen as described in the protocol
7. Subjects with systemic disease or other medical or psychiatric conditions that preclude safe participation in the study.
8. Subjects receiving immunosuppressive therapies, other than the immune modulating regimen described in this protocol, or any other therapy known to influence the immune system including but not limited to steroid implants, cytostatics, interferons, tumor necrosis factor (TNF)-binding proteins, drugs acting on immunophilins, or antibodies with known impact on the immune system.
9. Subjects of reproductive potential unwilling to use effective contraception starting right after ICF signature and for 12 months after SPVN06 SRI (i.e., no longer applicable to subjects of Cohort 4 after randomization).
10. Subjects who are pregnant or breastfeeding.
11. Subjects who are unwilling or unable (based on the investigator's judgment) to comply with the study protocol.
12. Subjects with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the investigator, would make them unsuitable for the study.
13. Subjects positive for human immunodeficiency virus (HIV) or any other systemic immunocompromising disease.
14. Subjects who have undergone, within 6 months before inclusion, any significant ocular surgery (per investigator's judgment) that could interfere with the evaluation of SPVN06 study objectives.
15. Presence of eye disorders that could interfere with the assessment of visual acuity and/or any other ocular assessments, including SD-OCT, during the study.
16. Presence of any systemic or ocular diseases, other than non-syndromic retinitis pigmentosa (RP), that can cause vision loss.
17. Prior full core vitrectomy or vitreomacular surgery in the Study Eye.
18. Presence of vitreomacular adhesion or traction, epiretinal membrane macular pucker or macular hole, evident by ophthalmoscopy and/or SD-OCT examinations and assessed by the investigator to significantly affect central vision.
19. Current evidence of retinal detachment assessed by the investigator to significantly affect central vision.
20. Active ocular inflammation or recurrent history of idiopathic or autoimmune-associated uveitis.
21. Subjects with presence of any suspected or active ocular or periocular infection (conjunctivitis, keratitis, scleritis, endophthalmitis).
22. Subjects with history of glaucoma.
23. Subjects with uncontrolled intraocular pressure (IOP).
24. Subjects with active cancer or currently receiving any therapy for cancer treatment.
25. Subjects with any history of ocular malignancy.
26. Subjects with a clinically significant cardiac disease on routine clinical examination (history, physical examination), or known congestive heart failure, myocardial infarction, clinically significant valvular heart disease, clinically significant cardiac rhythm or conduction abnormalities.
27. Subjects with unstable/uncontrolled hypertension, defined by national recommendations.
28. Subjects with pulmonary dysfunction or severe obstructive pulmonary disease.
29. Subjects with active tuberculosis.
30. Subjects with liver or renal insufficiency.
31. Subjects with unstable endocrine disease, including unstable diabetes or thyroid disease.
32. Subjects with active Hepatitis B or Hepatitis C.
33. Subjects with clinically active infection of herpetic diseases, including herpes simplex virus, varicella zoster virus (VZV), cytomegalovirus (CMV) or EBV.
34. Subjects with known history of ocular infection with herpes simplex virus.
35. Subjects with active (extraocular) infection (requiring or not the prolonged or chronic use of antimicrobial agents).
36. Immunocompromised subjects with previous solid organ or bone marrow transplant.
37. Subjects who receive a live vaccine less than 4 weeks prior to SPVN06 injection
38. Subjects who were infected by COVID-19 less than 2 weeks prior to SPVN06 injection.
39. Subjects who have recently received (less than 4 weeks) or plan to receive a COVID-19 vaccination.
40. Incapacitated subjects, as defined by national laws.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Step 1 : SPVN06 dose 1; Participants will receive a single subretinal injection of SPVN06 Dose 1 on Day 0.	Drug: SPVN06; AAV-RdCVF-RdCVFL
Experimental: Step 1 : SPVN06 dose 2; Participants will receive a single subretinal injection of SPVN06 Dose 2 on Day 0	Drug: SPVN06; AAV-RdCVF-RdCVFL
Experimental: Step 1 : SPVN06 dose 3; Participants will receive a single subretinal injection of SPVN06 Dose 3 on Day 0	Drug: SPVN06; AAV-RdCVF-RdCVFL
Experimental: Step 2 : SPVN06 Dose Recommended 1; Participants will receive a single subretinal injection of SPVN06 recommended dose 1 on Day 0	Drug: SPVN06; AAV-RdCVF-RdCVFL
Experimental: Step 2 : SPVN06 Dose Recommended 2; Participants will receive a single subretinal injection of SPVN06 recommended dose 2 on Day 0	Drug: SPVN06; AAV-RdCVF-RdCVFL
No Intervention: Step 2 : Control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD, 12 months after administration of gene therapy.	Incidence and severity of systemic and ocular AEs and SAEs	Baseline to 12 months after administration of gene therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of preliminary efficacy as assessed by visual acuity	BCVA change from baseline (EDTRS chart)	up to 5 years after treatment
Evaluation of preliminary efficacy as assessed by optical coherence tomography	Anatomical change from baseline (SD-OCT)	up to 5 years after treatment
Evaluation of preliminary efficacy as assessed by visual field	Change from baseline of static perimetry, kinetic perimetry and microperimetry	up to 5 years after treatment
Evaluation of preliminary efficacy as assessed by retinal sensitivity	Change from baseline of parameters collected by full-field electroretinography	up to 5 years after treatment
Evaluation of preliminary efficacy as assessed by retinal sensitivity	Change from baseline of parameters collected by FST	up to 5 years after treatment
Evaluation of preliminary efficacy as assessed by FAF	Change from baseline of parameters collected by fundus autofluorescence	up to 5 years after treatment
Evaluation of preliminary efficacy as assessed by quality of life	Change from baseline of parameters collected by VFQ-25	up to 5 years after treatment
Evaluation of preliminary efficacy as assessed by quality of life	Change from baseline of parameters collected by ViSIO-PRO	up to 5 years after treatment
Evaluation of viral shedding and bio-dissemination up to 1 year after treatment administration.	Quantification of viral DNA copies in tears (viral shedding) and in blood (bio-dissemination)	up to 1 year after treatment
Evaluation of the immune response against the viral vector and the transgene products of SPVN06 up to 5 years after treatment administration.	Titration of total antibodies against the viral capsid	up to 5 years after treatment
Evaluation of preliminary efficacy as assessed by color vision	Change from baseline of parameters collected by color vision assessment	up to 5 years after treatment
Evaluation of the long-term safety and tolerability of a single injection of SPVN06 in subjects with advanced RCD, up to 5 years after treatment administration.	Incidence and severity of systemic and ocular AEs and SAEs	up to 5 years after treatment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory objective - Exploration of biomarkers	Collect and store urine and blood (in addition to the body fluids used for the assessment of viral shedding and bio-dissemination) for further exploration of biomarkers of medical interest not already identified at time of protocol submission.	up to 5 years after treatment
Exploratory objective - Photoreceptor mosaic imaging	Collect and analyze photoreceptor mosaic images using adaptive optics	up to 5 years after treatment
Exploratory objective - Low luminance visual acuity (LLVA)	ETDRS for distance vision	up to 5 years after treatment

Collaborators and Investigators

• Sponsor: SparingVision

Publications and helpful links

General Publications

• Marie M, Churet L, Gautron AS, Farjo R, Mizuyoshi K, Stevenson V, Khabou H, Leveillard T, Sahel JA, Lorget F. Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies. Gene Ther. 2025 Aug 4. doi: 10.1038/s41434-025-00556-3. Online ahead of print.
• Clerin E, Yang Y, Pagan D, Achiedo S, Blond F, Millet-Puel G, Ait-Ali N, Harichane I, Degardin J, Cesar Q, Simonutti M, Bennett J, Zeitz C, Audo I, Cronin T, Leveillard T, Sahel JA. Combined Expression of hRdCVF and hRdCVFL Through AAV-Mediated Delivery for the Treatment of Retinitis Pigmentosa. Invest Ophthalmol Vis Sci. 2026 Mar 2;67(3):2. doi: 10.1167/iovs.67.3.2.

Study record dates

Study Major Dates

• Study Start (Actual): April 12, 2023
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): February 1, 2031

Study Registration Dates

• First Submitted: February 7, 2023
• First Submitted That Met QC Criteria: February 17, 2023
• First Posted (Actual): March 1, 2023

Study Record Updates

• Last Update Posted (Actual): May 15, 2026
• Last Update Submitted That Met QC Criteria: May 13, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Gene Therapy; Retinal Disease; Eye Disease; Retinal Degeneration; PDE6A; Rod-Cone Dystrophy; RHO; PDE6B; Pathogenic Mutation; Retinal Dystrophies
• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Eye Diseases, Hereditary; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cone-Rod Dystrophies; Retinal Diseases; Eye Diseases; Retinitis Pigmentosa; Retinal Degeneration; Retinal Dystrophies
• Other Study ID Numbers: SPVN06-CLIN-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes